查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472276

全球生物标记物市场：按类型、应用和服务 - 机会分析和产业预测，2024-2033 年

Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 347 Pages | 商品交期: 2-3个工作天内

价格

预计2023年全球生物标记市场规模将达464亿美元，2024年至2033年复合年增长率为11.2%，2033年将达1342亿美元。

生物标誌物市场-IMG1

生物标记是可测量的指标，提供有关生物过程、健康状况和治疗性介入反应的重要资讯。这些标记物存在于各种体液、组织或影像资料中，在疾病诊断、预后和监测中发挥重要作用。它作为一种客观、可量化的指标，帮助临床医生评估疾病的存在、严重程度和进展。生物标记包括广泛的蛋白质、核酸、代谢物和成像参数，反映了生物系统的多样性。

由于慢性病盛行率上升以及药物开发过程中生物标记物的采用率较高，预计生物标记物市场将在预测期内显着成长。

慢性病的增加已成为推动生物标记市场成长的关键因素。近年来，心血管疾病、癌症、糖尿病和神经退化性疾病的盛行率在全球范围内急剧上升。例如，世界卫生组织（WHO）2024年报告估计，到2050年将有超过3500万名新癌症患者被诊断出来。这种激增是由多种因素造成的，包括久坐的生活方式、不健康的饮食和人口老化。随着慢性病继续给医疗保健系统带来沉重负担，早期准确的诊断对于有效的疾病管理变得越来越重要。

生物标记是生物过程或状况的可测量指标，透过提供对个体生理状态的宝贵见解，在疾病诊断中发挥重要作用。生物标记有助于早期检测、风险评估和疾病进展监测，从而实现及时干预和个人化治疗策略。例如，美国生技公司 Guardant Health 提供 Guardant360 CDx 测试。 Guardant360 CDx 测试已获得 FDA核准作为所有固体癌的完整基因组测试。该测试可在基本血液检查后 7 天内提供全面的基因组测试结果，帮助医生做出明智的治疗方法选择。此外，基因组学、蛋白质组学和代谢体学的技术进步扩大了临床使用的生物标记的范围，并提高了其诊断各种疾病的有效性。因此，慢性病盛行率的增加预计将推动市场成长。

生物标记在药物开发过程中的快速采用是推动生物标记市场成长的关键因素。生物标记被定义为生物过程或治疗性介入的可测量指标，已成为药物开发过程中的重要工具。生物标记彻底改变了製药公司发现和开发药物的方式，因为它们可以提供有关生物体生理和分子生物学状态的准确、即时资讯。生物标记提供了一种客观评估新药从临床前测试到临床试验各个阶段的功效、安全性和潜在副作用的方法。这可以加快药物开发时间并增加成功的可能性。例如，根据国家医学图书馆 2020 年的一份报告，生物标记广泛应用于药物发现和开发的各个阶段。生物标誌物的使用有可能使药物发现、开发和核准过程更有效率。因此，在药物发现和开发过程中越来越多地采用生物标记预计将显着促进市场成长。

然而，资料安全和隐私问题已成为限制市场成长的主要问题。生命科学产业严重依赖收集、储存和分析大量敏感资料，包括病患记录、临床试验资讯和基因组资料。随着医疗保健流程变得更加数位化并采​​用云端运算和巨量资料分析等尖端技术，资料外洩和未授权存取的风险正在增加。因此，对资料安全和隐私的担忧预计将抑制市场成长。

此外，高昂的开发成本也可能抑制市场成长。生物标誌物的发现和检验需要大量的研究和开发成本。生物标誌物开发和检验的高成本对生物标誌物的采用产生负面影响，特别是在中小型企业中。

生物标誌物市场按类型、应用、服务和地区进行细分。依类型分为功效生物标记、安全生物标记和检验生物标记。依应用分为风险评估、分子诊断开发、疾病诊断、药物发现/市场开拓、製剂、法医学使用等。

依服务分类，可分为药物/样品製备、分析开发、生物标记验证/测试和其他服务。按地区：北美（美国、加拿大、墨西哥）、欧洲（法国、德国、义大利、西班牙、英国、英国其他地区）、亚太地区（中国、日本、印度、韩国、澳洲、亚太地区其他地区） ），太平洋地区的亚洲分析（巴西、日本、印度、韩国、澳洲、阿拉伯半岛和亚太其他地区）。

相关人员的主要利益

  • 该报告定量提供了2023年至2033年生物标记市场分析的细分市场、当前趋势、估计/趋势分析和动态，并确定了生物标誌物市场有前景的市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的力量。
  • 对生物标誌物市场细分的详细分析有助于识别市场机会。
  • 我们根据每个地区的主要国家对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前地位的清晰了解。
  • 该报告包括对区域和全球生物标记市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

该报告可以定制。

  • 根据客户兴趣加入公司简介
  • 按国家或地区分類的附加分析、市场规模和预测
  • 十字交叉细分市场分析、市场规模与预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）
  • 全球/区域/国家层级参与者的市场占有率分析
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 生物标记在药物发现和开发过程中的采用率很高。
      • 慢性病快速增加
      • 在法医学分析中更多地采用生物标记物。
    • 抑制因素
      • 生物标誌开发成本高
    • 机会
      • 私人组织与政府机构合作开发生物标记。

第四章生物标誌物市场：依类型

  • 概述
  • 功效生物标记
  • 安全生物标记
  • 验证生物标记

第五章生物标记市场：依应用分类

  • 概述
  • 风险评估
  • 分子诊断学的发展
  • 疾病诊断
  • 药物发现和药物开发
  • 药物製剂
  • 法医学应用
  • 其他的

第六章生物标记市场：依服务分类

  • 概述
  • 样品製备
  • 检测开发
  • 生物标记验证/测试
  • 其他服务

第七章生物标记市场：按地区

  • 概述
  • 北美洲
    • 北美药物发现和市场开拓生物标记市场：按类型
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲药物发现和市场开拓生物标记市场：按类型
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 亚太地区药物发现和市场开拓生物标记市场：按类型
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 拉丁美洲、中东和非洲的药物发现和市场开拓生物标记市场：按类型
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他拉丁美洲/中东/非洲

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2023年主要企业定位

第九章 公司简介

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Siemens AG
  • Thermo Fisher Scientific
  • Qiagen NV
  • Merck KGaA
  • F. Hoffmann-La Roche AG
  • Revvity, Inc.
Product Code: A00021

The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers Market - IMG1

Biomarkers are measurable indicators that provide essential information about biological processes, health conditions, or responses to therapeutic interventions. These markers, found in various bodily fluids, tissues, or even imaging data, play a crucial role in diagnostics, prognosis, and monitoring of diseases. They serve as objectifiable and quantifiable measures, aiding clinicians in assessing the presence, severity, and progression of illnesses. Biomarkers cover a broad spectrum, including proteins, nucleic acids, metabolites, and imaging parameters, reflecting the diverse nature of biological systems.

The biomarkers market is expected to register significant growth during the forecast period owing to a rise in incidence of chronic diseases and high adoption of the biomarkers in the drug development process.

The rise in incidence of chronic diseases has emerged as a pivotal driver propelling the growth of the biomarkers market. In recent years, there has been a noteworthy surge in the prevalence of conditions such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders globally. For instance, according to the 2024 report by World Health Organization, it was estimated that over 35 million new cancer cases are expected to be diagnosed in 2050. This surge is attributed to several factors, such as sedentary lifestyles, unhealthy dietary habits, and an aging population. As chronic diseases continue to impose a substantial burden on healthcare systems, there is an increase in emphasis on early and accurate diagnosis for effective disease management.

Biomarkers, which are measurable indicators of biological processes or conditions, play a crucial role in disease diagnosis by providing valuable insights into the physiological state of an individual. Biomarkers facilitate early detection, risk assessment, and monitoring of disease progression, enabling timely intervention and personalized treatment strategies. For instance, Guardant Health, an American biotechnology firm, provides Guardant360 CDx test. Guardant360 CDx test is FDA-approved for complete genomic testing for all solid cancers. The test delivers comprehensive genomic results within 7 days of a basic blood test, helping doctors make informed treatment choices. Furthermore, technological advancements in genomics, proteomics, and metabolomics have broadened the range of biomarkers for clinical use, improving their effectiveness in diagnosis of various diseases. Thus, the rise in the incidence of chronic diseases is expected to drive the growth of the market.

The surge in adoption of biomarkers in the drug development process stands as a pivotal driver propelling the growth of the biomarkers market. Biomarkers, defined as measurable indicators of biological processes or responses to therapeutic interventions, have become indispensable tools in the drug development process. The ability of biomarkers to provide precise and real-time information about the physiological and molecular status of an organism has revolutionized the way pharmaceutical companies approach drug discovery and development. Biomarkers offer a means to objectively assess the efficacy, safety, and potential adverse effects of new drugs at various stages, from preclinical studies to clinical trials. This expedites the drug development timeline and enhances the probability of successful outcomes. For instance, according to the 2020 report by the National Library of Medicine, biomarkers are widely used at every stage of drug discovery and development. Utilization of biomarkers has a potential to make drug discovery, development, and approval processes more efficient. Thus, the rise in adoption of biomarkers in the drug discovery and development procedure is expected to contribute significantly to the growth of the market.

However, data security and privacy concerns have emerged as major concerns that restrain the growth of the market. The life sciences industry relies heavily on the collection, storage, and analysis of vast amounts of sensitive and confidential data, including patient records, clinical trial information, and genomic data. With the increase in digitization of healthcare processes and the adoption of advanced technologies, such as cloud computing and big data analytics, the risk of data breaches and unauthorized access has escalated. Thus, data security and privacy concerns are expected to restrain the growth of the market.

In addition, high development costs might restrain the growth of the market. The discovery and validation of biomarkers involve significant R&D costs. The high cost of developing and validating biomarkers negatively impacts the adoption of the biomarkers particularly in smaller companies.

The biomarkers market is segmented on the basis of type, application, service, and region. By type, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. By application, the market is divided into risk assessment, development of molecular diagnostic, disease diagnosis, drug discovery & development, drug formulation, forensic application, and others.

By service, it is classified into pharmaceutical & sample preparation, assay development, biomarker validation & testing, and other services. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, rest of LAMEA)

The major players profiled in the report are GE Healthcare, Abbott Laboratories, Inc., Bio-Rad Laboratories, Epistem Ltd., Eisai Co. Ltd., Roche Diagnostics Limited, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aushon Biosystem, and Siemens AG.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biomarkers market analysis from 2023 to 2033 to identify the prevailing biomarkers market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the biomarkers market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • Market share analysis of players at global/region/country level
  • SWOT Analysis

Key Market Segments

By Type

  • Safety Biomarkers
  • Validation Biomarkers
  • Efficacy Biomarkers

By Application

  • Risk Assessment
  • Development of Molecular Diagnostic
  • Disease Diagnosis
  • Drug Discovery and Development
    • Type
    • Clinical Trial - Pre Clinical Phase and Phase 1
    • Clinical Trial Phase 2
    • Clinical Trial Phase 3
    • Clinical Trial Commercial Phase
  • Drug Formulation
  • Forensic Application
  • Others

By Services

  • Sample Preparation
  • Assay Development
  • Biomarker Validation and Testing
  • Other Services

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific
    • Qiagen N.V
    • F. Hoffmann-La Roche AG
    • GE Healthcare
    • Revvity, Inc.
    • Abbott Laboratories
    • Siemens AG
    • Merck KGaA
    • Agilent Technologies Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of biomarkers in drug discovery and development process.
      • 3.4.1.2. Surge in prevalence of chronic diseases.
      • 3.4.1.3. Rise in adoption of biomarkers in forensic analysis.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of development of biomarkers.
    • 3.4.3. Opportunities
      • 3.4.3.1. Collaborative efforts by private and government organizations for development of biomarkers.

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Efficacy Biomarkers
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Safety Biomarkers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Validation Biomarkers
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Risk Assessment
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Development of Molecular Diagnostic
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Disease Diagnosis
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Drug Discovery and Development
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
    • 5.5.4. Drug Discovery and Development Biomarkers Market by Type
      • 5.5.4.1. Clinical Trial - Pre Clinical Phase and Phase 1 Market size and forecast, by region
      • 5.5.4.2. Clinical Trial Phase 2 Market size and forecast, by region
      • 5.5.4.3. Clinical Trial Phase 3 Market size and forecast, by region
      • 5.5.4.4. Clinical Trial Commercial Phase Market size and forecast, by region
  • 5.6. Drug Formulation
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Forensic Application
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Others
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Sample Preparation
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Assay Development
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Biomarker Validation and Testing
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Other Services
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: BIOMARKERS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
      • 7.2.3.1. North America Drug Discovery and Development Biomarkers Market by Type
    • 7.2.4. Market size and forecast, by Services
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Services
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Services
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Services
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
      • 7.3.3.1. Europe Drug Discovery and Development Biomarkers Market by Type
    • 7.3.4. Market size and forecast, by Services
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. UK
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Services
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Services
      • 7.3.5.3. Germany
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Services
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Services
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Services
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Services
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
      • 7.4.3.1. Asia-Pacific Drug Discovery and Development Biomarkers Market by Type
    • 7.4.4. Market size and forecast, by Services
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Services
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Services
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Services
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Services
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Services
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Services
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
      • 7.5.3.1. LAMEA Drug Discovery and Development Biomarkers Market by Type
    • 7.5.4. Market size and forecast, by Services
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Services
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Services
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Services
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Services

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Agilent Technologies Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Bio-Rad Laboratories, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. GE Healthcare
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Siemens AG
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Thermo Fisher Scientific
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Qiagen N.V
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Merck KGaA
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. F. Hoffmann-La Roche AG
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Revvity, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 02. BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 06. BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 08. BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 11. BIOMARKERS MARKET FOR CLINICAL TRIAL - PRE CLINICAL PHASE AND PHASE 1, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 2, BY REGION, 2023-2033 ($MILLION)
  • TABLE 13. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 3, BY REGION, 2023-2033 ($MILLION)
  • TABLE 14. BIOMARKERS MARKET FOR CLINICAL TRIAL COMMERCIAL PHASE, BY REGION, 2023-2033 ($MILLION)
  • TABLE 15. BIOMARKERS MARKET FOR DRUG FORMULATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 16. BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 17. BIOMARKERS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 18. GLOBAL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 19. BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 20. BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 21. BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY REGION, 2023-2033 ($MILLION)
  • TABLE 22. BIOMARKERS MARKET FOR OTHER SERVICES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 23. BIOMARKERS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 28. NORTH AMERICA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 29. U.S. BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 30. U.S. BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 31. U.S. BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 32. CANADA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 33. CANADA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 34. CANADA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 35. MEXICO BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 36. MEXICO BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 37. MEXICO BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 38. EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 39. EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 40. EUROPE DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 41. EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 42. EUROPE BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 43. UK BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 44. UK BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 45. UK BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 46. FRANCE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 47. FRANCE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 48. FRANCE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 49. GERMANY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 50. GERMANY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 51. GERMANY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 52. ITALY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 53. ITALY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 54. ITALY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 55. SPAIN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 56. SPAIN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 57. SPAIN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 58. REST OF EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 59. REST OF EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 60. REST OF EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 66. JAPAN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 67. JAPAN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 68. JAPAN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 69. CHINA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 70. CHINA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 71. CHINA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 72. INDIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 73. INDIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 74. INDIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 75. AUSTRALIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 76. AUSTRALIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 77. AUSTRALIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 78. SOUTH KOREA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 79. SOUTH KOREA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 80. SOUTH KOREA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 84. LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 85. LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 86. LAMEA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 87. LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 88. LAMEA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 89. BRAZIL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 90. BRAZIL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 91. BRAZIL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 92. SAUDI ARABIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 96. SOUTH AFRICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 97. SOUTH AFRICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 98. REST OF LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 99. REST OF LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 100. REST OF LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 101. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 102. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 103. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 104. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 105. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 106. AGILENT TECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 107. AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 108. AGILENT TECHNOLOGIES INC.: PRODUCT SEGMENTS
  • TABLE 109. AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 110. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 111. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 112. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 113. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 114. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 115. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 116. GE HEALTHCARE: PRODUCT SEGMENTS
  • TABLE 117. GE HEALTHCARE: SERVICE SEGMENTS
  • TABLE 118. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 119. GE HEALTHCARE: KEY STRATERGIES
  • TABLE 120. SIEMENS AG: KEY EXECUTIVES
  • TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
  • TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
  • TABLE 124. SIEMENS AG: KEY STRATERGIES
  • TABLE 125. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
  • TABLE 126. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 127. THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
  • TABLE 128. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 129. THERMO FISHER SCIENTIFIC: KEY STRATERGIES
  • TABLE 130. QIAGEN N.V: KEY EXECUTIVES
  • TABLE 131. QIAGEN N.V: COMPANY SNAPSHOT
  • TABLE 132. QIAGEN N.V: PRODUCT SEGMENTS
  • TABLE 133. QIAGEN N.V: PRODUCT PORTFOLIO
  • TABLE 134. QIAGEN N.V: KEY STRATERGIES
  • TABLE 135. MERCK KGAA: KEY EXECUTIVES
  • TABLE 136. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 137. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 138. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 139. MERCK KGAA: KEY STRATERGIES
  • TABLE 140. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 141. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 142. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 143. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 144. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 145. REVVITY, INC.: KEY EXECUTIVES
  • TABLE 146. REVVITY, INC.: COMPANY SNAPSHOT
  • TABLE 147. REVVITY, INC.: PRODUCT SEGMENTS
  • TABLE 148. REVVITY, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. BIOMARKERS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF BIOMARKERS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN BIOMARKERS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN BIOMARKERS MARKET (2024-2033)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. BIOMARKERS MARKET, BY TYPE, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. BIOMARKERS MARKET, BY APPLICATION, 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG FORMULATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 23. BIOMARKERS MARKET, BY SERVICES, 2023 AND 2033(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHER SERVICES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 28. BIOMARKERS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 29. U.S. BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. CANADA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. MEXICO BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. UK BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. FRANCE BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. GERMANY BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. ITALY BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 36. SPAIN BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 37. REST OF EUROPE BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 38. JAPAN BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. CHINA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 40. INDIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 41. AUSTRALIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 42. SOUTH KOREA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 44. BRAZIL BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 45. SAUDI ARABIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 46. SOUTH AFRICA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 47. REST OF LAMEA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: BIOMARKERS MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2023
  • FIGURE 55. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. AGILENT TECHNOLOGIES INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 59. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 60. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 61. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. GE HEALTHCARE: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 65. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 66. GE HEALTHCARE: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 67. SIEMENS AG: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 68. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. SIEMENS AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 70. THERMO FISHER SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. QIAGEN N.V: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. QIAGEN N.V: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 75. MERCK KGAA: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 76. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 77. MERCK KGAA: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 78. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 79. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 80. REVVITY, INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 81. REVVITY, INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 82. REVVITY, INC.: REVENUE SHARE BY REGION, 2023 (%)